These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36682092)

  • 61. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.
    Gage JC; Schiffman M; Solomon D; Wheeler CM; Castle PE
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1668-74. PubMed ID: 20615884
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
    Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
    Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
    J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
    Wright TC; Stoler MH; Behrens CM; Sharma A; Zhang G; Wright TL
    Gynecol Oncol; 2015 Feb; 136(2):189-97. PubMed ID: 25579108
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Detection of cervical high-grade squamous intraepithelial lesions and assessing diagnostic performance of colposcopy among women with oncogenic HPV.
    Li X; Xiang F; Zhao Y; Li Q; Gu Q; Zhang X; Chen Z; Zhang M; Wang J; Liu R; Kang X; Wu R
    BMC Womens Health; 2023 Aug; 23(1):411. PubMed ID: 37542333
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall.
    Chiappetta C; Puggioni C; Lendaro E; Cacciotti J; Zaralli R; Migliore G; Bellardini P; Petrozza V; Della Rocca C; Di Cristofano C
    Int J Clin Exp Pathol; 2015; 8(12):16089-96. PubMed ID: 26884886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of Different HPV-based Strategies and Cytology in Routine Cervical Cancer Screening Programme in China: A Population-based Study.
    Wang S; Li L; Yang J; Han N; Bao H; Wang HJ
    Cancer Prev Res (Phila); 2022 Jan; 15(1):45-54. PubMed ID: 34556493
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
    Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
    J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Cook DA; Krajden M; Brentnall AR; Gondara L; Chan T; Law JH; Smith LW; van Niekerk DJ; Ogilvie GS; Coldman AJ; Warman R; Reuter C; Cuzick J; Lorincz AT
    Int J Cancer; 2019 May; 144(10):2587-2595. PubMed ID: 30412281
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Performance of Triage Strategies for Hr-HPV-Positive Women; A Longitudinal Evaluation of Cytology, p16/K-67 Dual Stain Cytology, and HPV16/18 Genotyping.
    Stanczuk G; Currie H; Forson W; Baxter G; Lawrence J; Wilson A; Palmer T; Arbyn M; Cuschieri K
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1492-1498. PubMed ID: 35511738
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optical Coherence Tomography Can Reduce Colposcopic Referral Rates in Patients With High-Risk Human Papillomavirus.
    Xiao X; Yan L; Yang X; Zhou Z; Shi L; Fu C
    J Low Genit Tract Dis; 2023 Oct; 27(4):324-330. PubMed ID: 37163703
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
    Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
    J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort.
    Bonde J; Bottari F; Parvu V; Pedersen H; Yanson K; Iacobone AD; Kodsi S; Landoni F; Vaughan L; Ejegod DM; Sandri MT
    Int J Cancer; 2019 Aug; 145(4):1033-1041. PubMed ID: 30895602
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
    Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
    Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
    Gilham C; Sargent A; Peto J
    BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.